Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for VIMKUNYA ® ...

Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2401 multi-center Phase 1 clinical trial evaluating ...

EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE Phase 1b ...

Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ...

Sumatra Slim Belly Tonic is not just another weight loss supplement, it’s a science-backed solution that aims to reset your ...

D-Bal MAX is a revolutionary new muscle-building supplement that will put you on the fast track to building lean muscle and ...

Tallmadge, Ohio, May 01, 2025 (GLOBE NEWSWIRE) -- Following Over 90 Days of Personal Experience, Here’s What Truly Occurred ...

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,450,742 A shares and 108,683,536 B shares. The number of votes of the company's shares is ...

Jean-Paul Clozel, Chairman of the Board of Idorsia, commented: “The team at Idorsia continues to go the extra mile to secure the company’s future. I would like to thank my colleagues on the Board for ...

CONCORD, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB) ("Ultrack" or the "Company") is pleased to announce it has entered into a Memorandum of Understanding (MOU) to ...

Comprehensive Healthcare today announced the expansion of its permanent supportive housing program in Sunnyside with the opening of Vista Del Sol-2 (VDS-2), a 20-unit long-term residential housing ...

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), today announced that it plans to submit a Q-Submission (“Q-Sub”) to the U.S. Food and Drug Administration (FDA) related to ...